Objective: O6-methylguanine-DNA methyltransferase (MGMT) repairs O6-methylguanine in DNA, therefore provides a tumor supressor effect. Type 2 transglutaminase (TGase-2) is a multifunctional enzyme involved in many biological processes. Few data are available in the literature on their expression in kidney cancers. In this preliminary study, we evaluated immunohistochemical expression of MGMT and TGase-2 in renal carcinoma cases. Method: Forty cases of renal carcinoma including ten clear cell, ten chromophobe cell, ten papillary and ten urothelial carcinoma were randomly selected. Thirty-one patients were male and average age was 61,5. Staining intensity and percentage of staining tumor cells were scored. Total score was categorized as weak, moderate and strong. Results: Strong MGMT positivity was demonstrated in 15 cases (38 %). Eight cases (20 %) showed strong TGase-2 expression. Fifty percent of clear cell carcinomas strongly expressed MGMT and TGase-2. No correlation was found between MGMT and/or TGase-2 expression, tumor size and grade. Eighty percent of urothelial carcinomas strongly expressed MGMT. Conclusion: The prognostic value of MGMT and TGase-2 as well as their potential role in treatment response have been investigated recently. MGMT and TGase-2 may be prognostic factors in renal carcinomas. Further investigation is required to verify our findings.